secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005014
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

ARS Pharma reports preliminary Q4 2024 neffy revenue of $6.5M, cash $314M
-------------------------------------------------------------------------

- Preliminary neffy net product revenue for Q4 2024 was approximately $6.5 million, total 2024 revenue $7.1 million since launch on Sept 23.
- Cash, cash equivalents and short-term investments were $314.0 million as of Dec 31, 2024, sufficient for at least three years.
- More than 14,500 neffy two-pack units delivered in Q4 2024; over 3,000 healthcare providers prescribed neffy to date.
- Express Scripts added neffy to commercial formularies in Nov 2024; targeting over 80% commercial coverage by Q3 2025.
- sNDA for neffy 1 mg (children 15-30 kg) has PDUFA date March 6, 2025; launch expected Q2 2025 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/0001193125-25-005014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer